<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353039</url>
  </required_header>
  <id_info>
    <org_study_id>GC6101A_P2</org_study_id>
    <nct_id>NCT02353039</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis</brief_title>
  <official_title>Double Blind, Multicenter, Randomized, Placebo-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C&amp;R Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRScube</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the investigational
      products in the patients with gastritis during their participation in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GC6101A is botanical drug products made from the Lonicerae Flos. Two hundred volunteers will
      participate in the study, receive 2-week treatment with GC6101A or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A percentage of subjects showed moderate improvement of stomach erosions by the endoscopy</measure>
    <time_frame>2 weeks</time_frame>
    <description>The definition of &quot;moderate improvement&quot; is the subjects showed score changed from 2-4 to 1 or from 4 to 2.
[score 1(normal) : no erosion, score 2(mild) : 1-2 erosions, score 3(moderate) : 3-5 erosions, score 4(severe) : 6 or more erosions]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A percentage of subjects showed significant improvement of stomach erosions by the endoscopy</measure>
    <time_frame>2 weeks</time_frame>
    <description>The definition of &quot;significant improvement&quot; is the subject showed score changed from 2-4 to 1.
[score 1(normal) : no erosion, score 2(mild) : 1-2 erosions, score 3(moderate) : 3-5 erosions, score 4(severe) : 6 or more erosions]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A percentage of subjects showed improvement of edema rating scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>The definition of &quot;improvement&quot; is the subjects showed score changed from 2 to 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A percentage of subjects showed improvement of erythema rating scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>The definition of &quot;improvement&quot; is the subjects showed reduction ratio of score changed 50% or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A percentage of subjects showed improvement of hemorrhage rating scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>The definition of &quot;improvement&quot; is the subjects showed reduction ratio of score changed 50% or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A percentage of subjects showed improvement of gastric symptom rating scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>The definition of &quot;improvement&quot; is the subjects showed reduction ratio of score changed 50% or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab results(Hematology, Blood chemistry, Urinalysis)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The results of physical examinations and Vital signs(body temperature, pulse)</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EKG results</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>GC6101A 37.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 12.5mg of GC6101A t.i.d for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC6101A 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 25mg of GC6101A t.i.d for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC6101A 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 50mg of GC6101A t.i.d for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administer placebo t.i.d for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC6101A 37.5mg</intervention_name>
    <description>Administer 12.5mg of GC6101A t.i.d for 2 weeks.</description>
    <arm_group_label>GC6101A 37.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC6101A 75mg</intervention_name>
    <description>Administer 25mg of GC6101A t.i.d for 2 weeks.</description>
    <arm_group_label>GC6101A 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC6101A 150mg</intervention_name>
    <description>Administer 50mg of GC6101A t.i.d for 2 weeks.</description>
    <arm_group_label>GC6101A 150mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administer placebo t.i.d for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is over 19 years old, men or women

          -  Patients diagnosed with acute or chronic gastritis by gastroscopy

          -  Patients with one or more erosions found by gastroscopy

          -  Signed the informed consent forms

        Exclusion Criteria:

          -  Patients who is impossible to receive gastroscopy

          -  Patients with peptic ulcer and gastroesophageal reflux disease

          -  Patients with gastroesophageal surgery and surgery to reduce the secretion of gastric
             acid (Except for surgery for perforated peptic ulcer and cecectomy)

          -  Patients with esophageal varix

          -  Patients with malignant neoplasm of gastrointestinal tract

          -  Patients with thrombosis or administered with anti-thrombotic drugs

          -  Patients with consumption coagulopathy

          -  Patients administered with H2 receptor antagonists, muscarinic receptor antagonists,
             gastrin receptor antagonist, proton pump inhibitors, prostaglandins or mucosal
             protective agents prior to study in 2 weeks

          -  Patient who cannot interrupt steroid, non-steroid anti-inflammatory drugs or aspirin
             during treatment

          -  Allergic or hypersensitive to any of the ingredients in the test products

          -  Pregnant or lactating female

          -  Patients who have abnormal baseline laboratory test result

          -  Patients taking other investigational drugs within 30 days prior to the study.

          -  Patients with Zollinger-Ellison syndrome

          -  Patients that investigators consider ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo Jin Park, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University, Gangnam Severance Hospital of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Min Kim, B.S.</last_name>
    <phone>+82-31-260-1936</phone>
    <email>dreamerkdm@greencross.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University, Busan Paik Hospital of Korea</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Ryong Ji, M.D. Ph.D.</last_name>
      <email>tokimom@nate.com</email>
    </contact>
    <investigator>
      <last_name>Sam Ryong Ji, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University, Dongsan Medical Center of Korea</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyeong Sik Park, M.D. Ph.D.</last_name>
      <email>seenae99@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Gyeong Sik Park, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonkwang University, Hospital of Korea</name>
      <address>
        <city>Iksan-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok Chae Choi, M.D. Ph.D.</last_name>
      <email>medcsc@wonkwang.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Seok Chae Choi, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University, Bundang Hospital of Korea</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Na Yeong Kim, M.D. Ph.D.</last_name>
      <email>nayoungkim49@empal.com</email>
    </contact>
    <investigator>
      <last_name>Na Yeong Kim, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungang University, Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Gyu Kim, M.D. Ph.D.</last_name>
      <email>jgkimd@cau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae Gyu Kim, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University, Medical Center of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Kyung Jung, M.D. Ph.D.</last_name>
      <email>junghk@ewha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hye Kyung Jung, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University, Seoul Paik Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Seop Moon, M.D. Ph.D.</last_name>
      <email>moonjs2@unitel.co.kr</email>
    </contact>
    <investigator>
      <last_name>Jeong Seop Moon, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kankbuk Samsung Medical Center of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Ho Park, M.D. Ph.D.</last_name>
      <email>pjho3@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeong Ho Park, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University, Guro Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Jae Park, M.D. Ph.D.</last_name>
      <email>gi7pjj@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Jong Jae Park, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University, Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Gyun Kim, M.D. Ph.D.</last_name>
      <email>harley1333@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Sang Gyun Kim, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University, Seoul Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Seong Lee, M.D. Ph.D.</last_name>
      <email>joonlee@schmc.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jun Seong Lee, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University, Seoul St. Mary's Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Myeong Park, M.D. Ph.D.</last_name>
      <email>parkjerry@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jae Myeong Park, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University, Gangnam Severance Hospital of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jin Park, M.D. Ph.D.</last_name>
      <email>hjpark21@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyo Jin Park, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University, Medical Center of Korea</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwang Jae Lee, M.D. Ph.D.</last_name>
      <email>kjleemd@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Gwang Jae Lee, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

